Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma

References

• Arkel Y S. Thrombosis and cancer. Semin Oncol 2000; 27: 362–374
   PubMed Web of Science ®Google Scholar
• Levitan N, Dowlati A, Remick S C, Tahsildar H I, Sivinski L D, Beyth R, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy; risk analysis using Medicare claims data. Medicine (Baltimore) 1999; 78: 285–291
   PubMed Web of Science ®Google Scholar
• Srkalovic G, Cameron M G, Rybicki L, Deitcher S R, Kattke-Marchant K, Hussein M A. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer 2004; 101: 558–566
   PubMed Web of Science ®Google Scholar
• Spicka I, Rihova Z, Kvasnicka J, Cieslar P, Prochazka B, Klener P. Disturbances of anticoagulation and fibrinolytic systems in monoclonal gammopathies-another mechanism of M-protein interference with hemostasis. Thromb Res 2003; 112: 297–300
   PubMed Web of Science ®Google Scholar
• Zangari M, Saghafifar F, Mehta P, Barlogie B, Fink L, Tricot G. The blood coagulation mechanism in multiple myeloma. Semin Thromb Hemost 2003; 29: 275–282
   PubMed Web of Science ®Google Scholar
• Coleman M, Vigliano E M, Weksler M E, Nachman R L. Inhibition of fibrin monomer polymerization by lambda myeloma globulins. Blood 1972; 39: 210–223
   PubMed Web of Science ®Google Scholar
• Dimopoulos M A, Eleutherakis-Papaiakovou V. Adverse effects of thalidomide administration in patients with neoplastic diseases. Am J Med 2004; 117: 508–515
   PubMed Web of Science ®Google Scholar
• Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001; 98: 492–494
   PubMed Web of Science ®Google Scholar
• Camba L, Peccatori J, Pescarollo A, Tresoldi M, Corradini P, Bregni M. Thalidomide and thrombosis in patients with multiple myeloma. Haematologica 2001; 86: 1108–1109
   PubMed Web of Science ®Google Scholar
• Coleman M, Leonard J, Lyons L, Pekle K, Nahum K, Pearse R, et al. BLT-D (clarithromycin [Biaxin], low-dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenström's macroglobulinemia. Leuk Lymphoma 2002; 43: 1777–1782
   PubMed Web of Science ®Google Scholar
• Osman K, Comenzo R, Rajkumar S V. Deep venous thrombosis and thalidomide therapy for multiple myeloma [letter]. N Engl J Med 2001; 344: 1951–1952
   PubMed Web of Science ®Google Scholar
• Rajkumar S V, Blood E, Vesole D, Fonseca R, Greipp P R. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24: 431–436
   PubMed Web of Science ®Google Scholar
• Zangari M, Anaissie E, Barlogie B, Badros A, Desikan R, Gopal A V, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001; 98: 1614–1615
   PubMed Web of Science ®Google Scholar
• Zangari M, Siegel E, Barlogie B, Anaissie E, Saghafifar F, Fassas A, et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood 2002; 100: 1168–1171
   PubMed Web of Science ®Google Scholar
• Zangari M, Barlogie B, Anaissie E, Saghafifar F, Eddlemon P, Jacobson J, et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol 2004; 126: 715–721
   PubMed Web of Science ®Google Scholar
• Weber D M, Rankin K, Delasalle K. Thalidomide alone and in combination for previously untreated multiple myeloma. VIII International Myeloma Workshop, Banff, Alberta, May, 4 – 82001, Abstract S66
   Google Scholar
• Jimenez V H, Dominguez V, Reynoso E, Lopez I. Thromboprophylaxis with aspirin for newly diagnosed multiple myeloma treated with thalidomide plus dexamethasone: a preliminary report [abstract 5091]. Blood 2006; 108: 362b
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006; 367: 825–831
   PubMed Web of Science ®Google Scholar
• Baz R, Li L, Kottke-Marchant K, Srkalovic G, McGowan B, Yiannaki E, et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc 2005; 80: 1568–1574
   PubMed Web of Science ®Google Scholar
• Schey S A, Fields P, Bartlett J B, Clarke I A, Ashan G, Knight R D, et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 2004; 22: 3269–3276
   PubMed Web of Science ®Google Scholar
• Zonder J A. Thrombotic complications of myeloma therapy. Hematol Am Soc Hematol Educ Program 2006; 348–355
   PubMedGoogle Scholar
• Streetly M, Hunt B J, Parmar K, Jones R, Zeldis J, Schey S. Markers of endothelial and haemostatic function in the treatment of relapsed myeloma with the immunomodulatory agent Actimid™ (CC-4047) and their relationship with venous thrombosis. Eur J Haematol 2005; 74: 293–296
   PubMed Web of Science ®Google Scholar
• Richardson P G, Blood E, Mitsiades C S, Jagannath S, Zeldenrust S R, Alsina M, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006; 108: 3458–3464
   PubMed Web of Science ®Google Scholar
• List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355: 1456–1465
   PubMed Web of Science ®Google Scholar
• Rajkumar S V, Hayman S R, Lacy M Q, Dispenzieri A, Geyer S M, Kabat B, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005; 106: 4050–4053
   PubMed Web of Science ®Google Scholar
• Dimopoulos M A, Spencer A, Attal M, Prince M, Harousseau J-L, Dmoszynska A, et al. Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma (MM): results of a phase 3 study (MM-010) abstract 6]. Blood 2005; 106: 6a
   Web of Science ®Google Scholar
• Coleman M, Leonard J, Lyons L, Szelenyi H, Niesvizky R. Treatment of Waldenstrom's macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone. Semin Oncol 2003; 30: 270–274
   PubMed Web of Science ®Google Scholar
• Niesvizky R, Bergsagel P L, Pearse R N, Schuster M W, Pekle K, Lyons L, et al. The addition of clarithromycin improves response to dexamethasone in chemotherapy naïve multiple myeloma patients [abstract 2342]. J Clin Oncol 2003; 22(suppl)582
   Google Scholar
• Niesvizky R, Pekle K, Lyons L, Pearse R N, Bersagel P L, Schuster M W, et al. Dexamethasone alone, or in combination with low-dose thalidomide as induction therapy for advanced multiple myeloma, and the effect of the addition of clarithromycin (Biaxin) on response rate: interim results of a prospective, sequential, randomized trial [abstract 832]. Blood 2003; 102: 237a
   PubMed Web of Science ®Google Scholar
• Niesvizky R, Martinez-Banos D M, Gelbshtein U, Cho H J, Pearse R N, Zafar F, et al. Prophylactic low-dose aspirin is effective as antithrombotic therapy in patients receiving combination thalidomide or lenalidomide [abstract 3454]. Blood 2005; 106: 964a
   Web of Science ®Google Scholar
• Hovens M M, Snoep J D, Tamsma J T, Huisman M V. Aspirin in the prevention and treatment of venous thromboembolism. J Thromb Haemost 2006; 4: 1470–1475
   PubMed Web of Science ®Google Scholar
• Weber D M, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer E, et al. Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): results of a North American phase III study (MM-009) [abstract 7521]. J Clin Oncol 2006; 24(18S part 1)427s
   Google Scholar
• Niesvizky R, Spencer A, Wang M, Weber D, Chen C, Dimopoulos M A, et al. Increased risk of thrombosis with lenalidomide in combination with dexamethasone and erythropoietin [abstract 7506]. J Clin Oncol 2006; 24(18S part 1)423s
   Google Scholar
• Knight R, DeLap R J, Zeldis J B. Lenalidomide and venous thrombosis in multiple myeloma [letter]. N Engl J Med 2006; 354: 2079–2080
   PubMed Web of Science ®Google Scholar
• Baz R, Walker E, Karam M A, Choueiri T K, Jawde R A, Bruening K, et al. Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Ann Oncol 2006; 17: 1766–1771
   PubMed Web of Science ®Google Scholar
• Zonder J A, Barlogie B, Durie B G, McCoy J, Crowley J, Hussein M A. Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. Blood 2006; 108: 403
   PubMed Web of Science ®Google Scholar
• Minnema M C, Breitkreutz I, Auwerda J JA, van der Holt B, Cremer F W, van Marion A MW, et al. Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy [letter]. Leukemia 2004; 18: 2044–2046
   PubMed Web of Science ®Google Scholar
• Arkel Y S, Ku D WH, Le P. Effect of thalidomide on tissue factor activity in monocytic and endothelial cell lines, and relationship to tumor necrosis factor-α (TNF) [abstract]. Blood 2001; 98: 52b
   Web of Science ®Google Scholar
• Arkel Y S, Ku D-HW, Thurston A L. The effect of thalidomide on tissue factor activity in Mono Mac 6 cells and the relationship to tumor necrosis factor (TNF)-α-stimulated cells. J Thromb Haemost 2003; 1: 2691–2692
   PubMed Web of Science ®Google Scholar
• Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006; 354: 1021–1030
   PubMed Web of Science ®Google Scholar
• Miller K C, Manochakian R, Padmanabhan S, Coignet J-G, Musial L, DePaolo D, et al. Weight adjusted low-dose warfarin decreases the incidence of thalidomide (T) associated venous thromboembolism (VTE) in patients (pts) with multiple myeloma (MM) and Waldenstroms macroglobulinemia (WM) [abstract 4101]. Blood 2006; 108: 105b
   Web of Science ®Google Scholar
• Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21: 16–19
   PubMed Web of Science ®Google Scholar
• Hirsh J. Risk of thrombosis with lenalidomide and its prevention with aspirin. Chest 2007; 131: 275–277
   PubMed Web of Science ®Google Scholar
• Rajkumar S V, Jacobus S, Callander N, Fonseca R, Vesole D, Greipp P. A randomized phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group [abstract 799]. Blood 2006; 108: 239a
   Web of Science ®Google Scholar
• Mitchell J A, Akarasereenont P, Thiemermann C, Flower R J, Vane J R. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 1993; 90: 11693–11697
   PubMed Web of Science ®Google Scholar
• Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994; 330: 1287–1294
   PubMed Web of Science ®Google Scholar
• Clarke R J, Mayo G, Price P, FitzGerald G A. Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med 1991; 325: 1137–1141
   PubMed Web of Science ®Google Scholar
• Durie B GM, Richardson P, Palumbo A, Dimopoulos M A, Cavo M, Hajek R, et al. Deep vein thrombosis in myeloma: estimate of prevalence and recommendations for therapy based upon a survey of members of the International Myeloma Working Group (IMWG) [abstract 3571]. Blood 2006; 108: 1020a
   Web of Science ®Google Scholar